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Background:
Postherpetic neuralgia (PHN) is a serious complication resulting from herpes zoster infections, and it can 
impair the quality of life. In order to relieve pain from PHN, various treatments, including pharmacological 
and interventional methods have been used. However, little information on the recommendations for the 
interventional treatment of PHN, along with a lack of nation-wide surveys on the current status of PHN 
treatment exists. This multicenter study is the first survey on the treatment status of PHN in Korea.
Methods:
Retrospective chart reviews were conducted on the entire patients who visited the pain clinics of 11 teaching 
hospitals from January to December of 2011. Co-morbid disease, affected site of PHN, routes to pain clinic 
visits, parenteral/topical medications for treatment, drugs used for nerve block, types and frequency of nerve 
blocks were investigated.
Results:
A total of 1,414 patients’ medical records were reviewed. The most commonly affected site was the thoracic 
area. The anticonvulsants and interlaminar epidural blocks were the most frequently used pharmacological and 
interventional methods for PHN treatment. For the interval of epidural block, intervals of 5 or more-weeks 
were the most popular. The proportion of PHN patients who get information from the mass media or the 
internet was only 0.8%.The incidence of suspected zoster sine herpete was only 0.1%.
Conclusions:
The treatment methods for PHN vary among hospitals. The establishment of treatment recommendation for 
PHN treatment is necessary. In addition, public relations activities are required in order to inform the patients 
of PHN treatments by pain clinicians. (Korean J Pain 2013; 26: 21-26)
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Table 1. Patients’ Demographics
Parameter Data
Gender (M/F)
Age (years)
Period before treatment (months)
528/886 (total 1,414 patients)
66.2 ± 12.3 years
Range 0−312 (median 1)
Data presented as mean ± standard deviation. 
INTRODUCTION
Postherpetic neuralgia (PHN) is the most debilitating 
and common complications of herpes zoster (HZ). Pain 
from PHN causes adverse impacts on the quality of life of 
patients, especially in the elderly [1]. Although there is no 
consensus on the precise definition of PHN, in general, 
pain which may persist for months or years after the heal-
ing of skin lesions at the HZ site is generally considered 
PHN. According to an epidemiologic study, the incidence 
of persistent pain is 19.5% and 13.7% 1 and 3 months after 
HZ, respectively [2]. It is also reported that the incidence 
of PHN increases with age, about 10-20% of patients aged 
over 50, experience PHN after HZ infection, and about 
30% of patients aged over 80, experience PHN [2,3]. Also, 
PHN causes social issues because of its high prevalence 
in the elderly and economic burden on the national health 
care system [4]. For the treatment of PHN, both pharma-
cologic and non-pharmacologic methods have been used 
[5]. There have been many efforts to optimize the medical 
treatment of PHN [6,7], thus as a result, the medical 
treatment of PHN is performed according to the available 
pharmacologic treatment guidelines or recommendations. 
Nevertheless, the management of PHN is often suboptimal 
[8]. In the field of pain medicine, many pain practitioners 
perform various interventional treatments for PHN, and 
new methods are being applied [9,10]. However, there is 
little information on the recommendations or practice 
guidelines for the interventional treatment of PHN, which 
forces pain clinicians to apply different interventional 
methods in the treatment of PHN. Therefore, considerable 
variations throughout Korea are being applied in the inter-
ventional treatment methods for PHN. To overcome this 
problem, the ‘Research and Development Committee’ of 
the Korean Pain Society decided to conduct a multicenter 
survey on the treatment of PHN in Korea. This is the first 
multicenter study on the current status of PHN treatment 
in Korea. We think that this study will be baseline data 
in establishing the recommendations for PHN treatment. 
MATERIALS AND METHODS
A total of 11 teaching hospitals, a part of the Korean 
Pain Society, participated in this study. This study was ap-
proved by the institutional review board of each hospital. 
In these hospitals, interventional pain management is con-
ducted by a certified pain specialist. We conducted retro-
spective chart reviews on patients who met the following 
criteria; ① new-visit or first visit patients to the pain clin-
ic of the 11 hospitals during the periods from January to 
December 2011, and ② patients who complained of herpes 
zoster related pain, regardless of the duration of the 
symptoms. For the retrospective chart reviews, the in-
formation for the following items were collected from each 
patient: age, sex, period before PHN treatment, co-morbid 
disease, PHN site, routes to pain clinic visit, paren-
teral/topical medications for treatment, types and fre-
quency of nerve blocks, additives used for nerve blocks, 
and other treatment methods used. PASWⓇ version 17.0 
software (Chicago, IL, USA) was used for the statistical 
analysis. Descriptive statistical analyses were conducted 
from these data and the results are expressed as fre-
quency, percentage, and means ± standard deviation (SD). 
RESULTS
1. General information on the study subjects
A total of 1,414 patients from 11 hospitals were enrolled 
for this study. The period before PHN treatment was 
ranged from 0 to 312 months (median 1 month). The dem-
ographic data were presented in the Table 1.
2. Co-morbid disease 
Among the data available for the 1,361 patients, only 
274 patients (20.1%) had co-morbid disease, which were 
related to immune problems; diabetes (192 patients, 14.1%), 
cancer (75 patients, 5.5%), and immune-suppression (7 
patients, 0.5%). However, contrary to our expectations, 
603 patients (44.3%) had other chronic diseases that were 
not related to immune-compromised states (e.g., hyper-
tension or hypercholesterolemia, etc.), and the remaining 
496 patients (36.4%) were free from any co-morbid 
diseases. 
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Fig. 1. Affected site of postherpetic neuralgia. The most 
commonly affected site was thoracic area and followed by
trigeminal area.
Fig. 2. Parenteral and topical medications used for PHN 
treatment. The most frequently used medication was 
anticonvulsants.
Fig. 3. Local anesthetics used for nerve blocks. Mepi-
vacaine was the most frequently used.
3. Affected PHN sites
The most commonly affected site was the thoracic area 
(772 patients, 52.9%), followed by the trigeminal area (228 
patients, 15.6%; V1/V2/V3 = 136/54/38). The suspected 
zoster sine herpete (ZSH) was only found in 2 patients 
(0.1%). The affected PHN sites are presented in Fig. 1.
4. Route of pain clinic visit
Only the data for 881 patients were available for this 
retrospective study. Among these cases, the main route for 
the pain clinic visit was through a referral from another 
department of the hospital (711 patients, 80.7%). Other 
patients visited the pain clinic without any referrals; via 
recommendations for pain clinic visits by acquaintances (31 
patients, 3.5%), via internet searching (4 patients, 0.5%), 
and via mass media (newspaper, TV, and radio, 3 patients 
0.3%). The remaining patients (15.0%) visited the pain 
clinic via other routes. 
5. Parenteral or topical medications
A total of 1,362 patients’ data for this category was 
available, with most of these patients taking a combination 
of 2 or more kinds of medication. The most frequently used 
medication was anticonvulsants (1,141 cases, 83.8%), fol-
lowed by acetaminophen/non-steroidal anti-inflammatory 
drugs (NSAIDs) (773 cases, 56.8%), tricyclic antidepressants 
(TCA) (742 cases, 54.5%), tramadol (725 cases, 53.2%), 
and opioids (251 cases, 18.4%). Fig. 2 illustrates the paren-
teral/topical medications used for the treatment of PHN.
6. Nerve block types performed 
A total of 1,398 patients were available, among them, 
1,184 patients were affected with PHN at the spinal (from 
cervical to sacral dermatome) region, and 214 patients 
were affected at the craniofacial region. In the 1,184 pa-
tients who were affected with PHN at the spinal area, a 
total of 1,126 patients received nerve blocks; interlaminar 
(IL) epidural injection was the most frequently performed 
(368 cases, 32.7%), followed by peripheral nerve block (317 
cases, 28.2%), transforaminal (TF) epidural injection (219 
cases, 19.4%), paravertebral block (113 cases, 10.0%), and 
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Fig. 4. Distribution of nerve block intervals. (A) Epidural 
block, (B) sympathetic block, (C) peripheral block, (D) 
paravertebral block, and (E) cranial nerve block. There are 
2 peaks in the distribution of each blocks.
sympathetic block (109 cases, 9.7%). In the 214 patients 
who were affected with PHN at the craniofacial area, a to-
tal of 208 patients received nerve blocks; on the contrary 
to the patients who were affected with PHN at the spinal 
region, the sympathetic block was most frequently per-
formed (87 cases, 41.8%) in the craniofacial region. Cranial 
nerve block and peripheral nerve block were performed in 
77 cases (37.0%) and 44 cases (21.2%), respectively, both 
performed in the craniofacial region. The local anesthetics 
used for the nerve block are illustrated in Fig. 3.
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Table 2. Mean Dosage of Additives for Single Nerve Block
Drugs Dosage (mg)
Triamcinolone
Dexamethadone
Betamethasone
Ketamine
19.9 ± 12.2
4.7 ± 1.2
3.6 ± 3.0
7.7 ± 3.8
Data presented as mean ± standard deviation. 
7. Interval of nerve blocks
A total of 457/183/350/196/128 patients’ data were 
available for epidural (interlaminar or transforaminal)/ 
sympathetic/peripheral/paravertebral/cranial nerve block, 
respectively. There were 2 distinctive peaks in the dis-
tribution for the injection intervals. For the epidural in-
jections, 5 or more-week intervals were the most popular 
(162 patients, 35.4%), followed by the 1-week intervals (116 
patients, 25.4%). The sympathetic blocks were performed 
with short intervals; mainly performed with 1 week inter-
vals (59 patients, 32.2%). For the peripheral nerve blocks, 
5 or more-week intervals were the most popular (118 pa-
tients, 33.7%), followed by the twice-a-week intervals (84 
patients, 24.0%). For the paravertebral block, the most 
popular interval was the 5 or more-week intervals (62 pa-
tients, 31.5%), followed by the 1 week intervals (58 patients, 
29.4%). For the cranial nerve block, twice-a-week inter-
vals and 5 or more-week intervals were equally popular 
(35 patients, 27.3%), Fig. 4 illustrates the intervals of each 
type of block.
8. Intravenous infusion therapy
Intravenous infusion treatments were used in 335 pa-
tients; ketamine (58 patients, 17.3%), magnesium (48 pa-
tients, 14.3%), lidocaine (25 patients, 7.5%), vitamin C (29 
patients, 8.7%), and multi-vitamin and/or other drugs (175 
patients, 51.9%). 
9. Additives for the nerve blocks
A total of 963 patients’ data were available. Triamci-
noline acetonide was the most frequently used additive for 
the nerve blocks (509 patients, 52.9%), followed by ket-
amine (149 patients, 15.5%), betamethasone (63 cases, 
6.5%), and dexamethasone (52 patients, 5.4%). Magnesium 
and other additives were used in 190 cases (19.7%). The 
mean dosage of the additives employed for the single nerve 
blocks are described in Table 2.
10. Other treatments
Among the 1,414 patients, pulsed radiofrequency (RF) 
lesioning and heat RF were performed only on 70 (4.95%) 
and 14 patients (0.99%), respectively. Only 1 patient 
(0.07%) received both pulsed and heat RF in combination. 
The intrathecal steroid injection was performed on 3 pa-
tients (0.21%), and alcohol neurolysis was performed on 4 
patients (0.28%).
DISCUSSION
In this study, we found that anticonvulsants were the 
most frequently used in the treatment of PHN, which is 
in accord with the findings of the previous guidelines for 
neuropathic pain management [7,11]. However, there were 
considerable variations in applying interventional treat-
ments, especially for the intervals of the nerve block; the 
nerve blocks were performed with 1 week intervals or in-
tervals of 5 or more weeks (2 distinctive peaks). These 
findings meant that there was no consensus on the proper 
interval for nerve block treatment of PHN. Although there 
have been several interventional treatment guidelines for 
spinal pain [8,12,13], there is no information available on 
how to apply and when to apply these interventional meth-
ods for the treatment of PHN. Moreover, whether epidural 
steroid administration itself has an additive effect on the 
remedy of PHN is also questioned [14]. Therefore, further 
studies or expert meetings are required to establish rec-
ommendations for the interventional treatment of PHN. 
The most frequently used nerve block for PHN in the 
spinal region was IL epidural injection; this may be due to 
the result of the ease in performing this procedure, be-
cause the IL approach is usually performed in a blind 
manner. Although there are no comparative studies on the 
effect of interlaminar and transforaminal injections for 
PHN treatment, based on the fact that the TF approach 
has advantages over the IL approach due to its precise 
flow to the targeted dorsal root ganglion and spinal nerve 
with the smallest volume, there is no evidence and there 
seems to be no specific reason to prefer the IL approach 
over the TF approach in the epidural injection for PHN 
treatment. 
In our study, the incidence of suspected ZSH was 
0.2%. ZSH is difficult to diagnose and is often confused 
with other diseases [15] because it does not have the typi-
cal vesicular skin lesions. Currently, there is no information 
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available on the incidences of ZSH. Although the incidence 
of ZSH in our study is not proven serologically, based on 
the clinical suspicion of ZSH however, the results seem to 
be the first report on the incidence of ZSH among PHN 
patients. 
For the co-morbid disease, only 274 patients (20.1%) 
had co-morbid diseases which were related to compro-
mised immunity, and 496 patients (36.4%) were free from 
any co-morbid diseases. These findings suggest that even 
a healthy elderly person, who does not have any co-morbid 
diseases, can suffer from PHN, and the zoster vaccine can 
be beneficial for the prevention of herpes zoster and PHN 
in these elderly patients.
There are some limitations to our study. First, this is 
a retrospective study therefore, large amounts of missing 
or unknown data existed. To overcome this problem, pro-
spective cohort studies are required. Second, this study in-
cluded only teaching hospitals in Korea. At the initial plan-
ning stages of this survey, the Korean Pain Society sent 
official mail to all society members to participate in this 
survey however, there were only responses from 11 teach-
ing hospitals, and none from private hospitals. Therefore, 
the results of this survey may not reflect the circum-
stances of private hospitals. Third, this survey did not in-
vestigate the treatment effects of each interventional 
treatment. In this survey, we did not focus on ‘which 
treatment is effective’, but on the ‘how PHN is treated in 
Korea’. Although the topic of ‘what is the best practice 
for PHN treatment’ cannot be answered in our study, we 
think that the results of our study can be a cornerstone 
in the development of treatment strategies for PHN. 
Further research should be carried out to obtain more 
conclusive information. In conclusion, the methods for PHN 
treatment vary among hospitals. The establishment of 
treatment recommendations for PHN is necessary as a 
result.
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